Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM

New drugs are needed for the treatment of relapsed acute lymphoblastic leukemia and preclinical evaluation of the MEK inhibitor, selumetinib, has shown that this drug has excellent activity in those leukemias with RAS pathway mutations. The proapoptotic protein, BIM is pivotal in the induction of ce...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Matheson, Elizabeth C., Thomas, Huw, Case, Marian, Blair, Helen, Jackson, Rosanna K., Masic, Dino, Veal, Gareth, Halsey, Chris, Newell, David R., Vormoor, Josef, Irving, Julie A.E.
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6717586/
https://ncbi.nlm.nih.gov/pubmed/30655370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.185975
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados